FDA Sends CBD Report to Congress That Fails To Give Specifics on Moving Forward

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Sends CBD Report to Congress That Fails To Give Specifics on Moving Forward

Darla M. Fera

March 16, 2020 at 02:22 PM EST

A new report to Congress from the FDA indicates that the agency will continue its rather thoughtful, deliberative approach to regulating the use of products containing cannabidiol (CBD), including as a dietary supplement. The Joint Explanatory Statement accompanying the Consolidated Appropriations Act of 2020 (Pub. L. 116-94), signed by the president on Dec. 20, 2019, directe... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Sends CBD Report to Congress That Fails To Give Specifics on Moving Forward

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Sends CBD Report to Congress That Fails To Give Specifics on Moving Forward

My Research Folders

Related Articles

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT